Visit Aggrego Advances hub to learn more about the late breaking developments from the POSEIDON trial 

Friday
December
01
Top Stories

Spotlight

Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy.